IRMS

CCRM FERTILITY WELCOMES REGIONAL DIRECTOR OF CLINICAL REPRODUCTIVE GENETICS, DR. JASMINE ALY, TO JERSEY CITY TEAM

Retrieved on: 
Wednesday, March 27, 2024
ART, WRNMMC, Obstetrics, PCOS, Gynaecology, Obesity, Polycystic disease, Reproductive Sciences, Science, NHGRI, Genetic distance, FACOG, Genetics, COVID-19, Patient, Empathy, Medical genetics, Cooper University Hospital, Research, African Americans, USUHS, Fibroid, Reproduction, Assisted reproductive technology, IRMS, NIH, Polycystic ovary syndrome, Outline of health sciences, Reproductive endocrinology and infertility, Publication, Fertility, REI, Birth control

JERSEY CITY, N.J., March 27, 2024 /PRNewswire/ -- CCRM Fertility, a leading pioneer in the fertility treatment, research, and science industry, announced today that Jasmine Aly, MD, FACOG, will be joining  CCRM | IRMS in New Jersey. Dr. Aly holds the rare distinction of being a triple-specialized physician as an Obstetrician-Gynecologist, Reproductive Endocrinologist, and Medical Geneticist.

Key Points: 
  • JERSEY CITY, N.J., March 27, 2024 /PRNewswire/ -- CCRM Fertility, a leading pioneer in the fertility treatment, research, and science industry, announced today that Jasmine Aly, MD, FACOG, will be joining  CCRM | IRMS in New Jersey.
  • As Regional Director of Clinical Reproductive Genetics, Dr. Aly will bring her expertise to the CCRM Fertility team and aims to leverage her comprehensive fellowship training in genetics to further advance the field and better serve patients.
  • As an esteemed reproductive endocrinologist, she will utilize cutting-edge  technology and innovative scientific techniques to ensure patient success rates continue to rise.
  • "Dr. Aly's expertise in genetics is an invaluable attribute that will redefine care at CCRM | IRMS," notes CCRM Fertility CEO, Bob LaGalia.

New CCRM Fertility Location Opens in Jersey City, NJ

Retrieved on: 
Thursday, January 11, 2024
Patient, Fertility, MD, Infertility, IVF, University Medical Center, Johns Hopkins, University, Johns Hopkins Hospital, IRMS, IUI, York Street, NYU Langone Health, Birth control

JERSEY CITY, N.J., Jan. 11, 2024 /PRNewswire/ -- CCRM Fertility is opening a new clinic location in Jersey City to provide patients with greater access to its full array of fertility treatments and services in New Jersey. This now totals eight locations in New Jersey, which became part of the CCRM network when IRMS was acquired in June 2022. All existing IRMS locations will be rebranded to CCRM Fertility by 2025.

Key Points: 
  • JERSEY CITY, N.J., Jan. 11, 2024 /PRNewswire/ -- CCRM Fertility is opening a new clinic location in Jersey City to provide patients with greater access to its full array of fertility treatments and services in New Jersey.
  • The new, state-of-the-art Jersey City location will be led by Dr. Stephanie Marshall Thompson, MD and Dr. Serena H. Chen, MD .
  • "We are thrilled to open another location in the Tri-State Area," said CEO CCRM Fertility Bob LaGalia.
  • "I'm excited to expand CCRM further and bring top-tier fertility care to patients in Jersey City," said Dr. Thompson.

Anju's TA Scan Expands Global Reach with European Diversity Data Integration

Retrieved on: 
Tuesday, October 17, 2023
Data science, ChromeOS, Scan, Anju, Privacy, IRMS, Patient, Medical device

FT. LAUDERDALE, Fla., Oct. 17, 2023 /PRNewswire/ -- Anju, a leading provider of clinical intelligence solutions, proudly announces the expansion of its TA Scan platform through the integration of European diversity data from the UK and demographics data from France and Spain.

Key Points: 
  • FT. LAUDERDALE, Fla., Oct. 17, 2023 /PRNewswire/ -- Anju, a leading provider of clinical intelligence solutions, proudly announces the expansion of its TA Scan platform through the integration of European diversity data from the UK and demographics data from France and Spain.
  • This strategic enhancement, implemented in September 2023, builds upon Anju's commitment to supporting global clinical research diversity and site selection.
  • Anju's dedication to delivering comprehensive, global diversity data empowers clinical research professionals to meet these emerging requirements efficiently, while maintaining the highest standards of data security and privacy.
  • "TA Scan's expansion into European diversity data underscores our commitment to helping clinical research professionals meet their global study diversification goals," said Barbara Argibay, VP of Development, Data Division at Anju.

Anju to Showcase TA Scan's Global Diversity Data at SCOPE Europe 2023 and Compete for Best of Show Award

Retrieved on: 
Thursday, October 12, 2023
Anju, SCOPE, Data science, Forecasting, Trial of the century, Feasibility, IRMS, Pharmaceutical industry

Anju is proud to showcase TA Scan, their innovative clinical intelligence solution, to this global audience.

Key Points: 
  • Anju is proud to showcase TA Scan, their innovative clinical intelligence solution, to this global audience.
  • As an exhibitor at SCOPE Europe 2023 , Anju will vie for the esteemed Best of Show Award, recognizing the most innovative and impactful solutions in the clinical research industry.
  • Anju invites attendees to visit booth #16 to explore TA Scan and discover how it can revolutionize trial planning and execution.
  • Anju is a portfolio company of Abry Partners serving the worldwide pharmaceutical, biotech and contract research Life Sciences markets.

Oova, Inc.'s Study Harnesses Hormone Data and Age to Precisely Determine Cycle Day within the Menstrual Cycle

Retrieved on: 
Thursday, August 3, 2023
Menstrual cycle, Pregnancy, Luteal phase, Obstetrics, Urine, Ovulation, IRMS, Follicular phase, LH, Woman, Research, Doctor of Philosophy, Luteinizing hormone, MD, Collection, PCOS, Patient, Gynaecology, Textbook, Key finding attacks, St. Barnabas' Hospital (Osaka), Massachusetts General Hospital, Female, Birth control, Medicina, MDPI

NEW YORK, Aug. 3, 2023  /PRNewswire-PRWeb/ -- Oova, Inc. is proud to announce the publication of its latest groundbreaking study in MDPI journal, Medicina, titled "Using Hormone Data and Age to Pinpoint Cycle Day within the Menstrual Cycle." Conducted by esteemed scientists and co-authors, led by Dr. Amy Divaraniya, PhD founder of Oova, Inc., Dr. Mark B. Woodland, MD, Chair of Obstetrics and Gynecology at Tower Health, and Elinor Hills, content and brand lead at Oova, Inc, their discoveries bring a new understanding of the female reproductive cycle, particularly women with irregular periods, and confirms just how advanced and accurate remote hormone tracking has become.

Key Points: 
  • NEW YORK, Aug. 3, 2023 /PRNewswire-PRWeb/ -- Oova, Inc. is proud to announce the publication of its latest groundbreaking study in MDPI journal, Medicina, titled " Using Hormone Data and Age to Pinpoint Cycle Day within the Menstrual Cycle ."
  • Adding to Oova's extensive collection of research and data on women's hormone levels, the study challenges the standard norms used for comparison and disproves the assumption of a 28-day reproductive cycle.
  • In this study, the Oova team evaluated hormone data from 4,123 cycles across 1,233 users, analyzing and tracking the LH and PdG via urine tests throughout menstrual cycles across different age groups.
  • Using Oova's hormone data to train their algorithm, Oova can now determine a woman's cycle day based on her age and hormone levels with 95% confidence.

CCRM Fertility IRMS Reproductive Medicine Continues to Expand with New Office in Princeton, New Jersey

Retrieved on: 
Tuesday, June 6, 2023
University of Vermont, Reproductive medicine, Robert Larner College of Medicine, Bellevue Hospital, NYU, New York University Grossman School of Medicine, IRMS, DRS, Wellesley College, Infertility, Multimedia, Harvard University, Gynaecology, IVF, Suite, IUI, Weill Cornell Medicine, Fertility, Cornell University, Patient, University, Obstetrics, Johns Hopkins, Birth control, Medical device, Nursing, Princeton University, Medicine

PRINCETON, N.J., June 6, 2023 /PRNewswire/ -- CCRM Fertility IRMS Reproductive Medicine is excited to announce the opening of a stunning new office in Princeton, New Jersey .

Key Points: 
  • PRINCETON, N.J., June 6, 2023 /PRNewswire/ -- CCRM Fertility IRMS Reproductive Medicine is excited to announce the opening of a stunning new office in Princeton, New Jersey .
  • Last June, IRMS Reproductive Medicine joined the CCRM Fertility network and is currently operating under the name CCRM Fertility IRMS Reproductive Medicine.
  • CCRM Fertility IRMS Reproductive Medicine has served patients at multiple New Jersey and New York locations for close to thirty years.
  • She brings a tremendous amount of experience to CCRM Fertility IRMS Reproductive Medicine's clinical practice and valued patients.

Introducing Frida Fertility, a New Line of Simple Solutions for the Not-so-Simple Act of Babymaking

Retrieved on: 
Wednesday, May 17, 2023
Women, Other Retail, Men, Parenting, Family, Baby, Maternity, Consumer, Retail, ACT, Insurance, Pressure, Male, Partnership, Cooperman Barnabas Medical Center, NOT, Life, Internet, Culture, Parent, Ovulation, CVS, IRMS, Woman, Multimedia, The Institute, Coenzyme Q10, Vitamin D, Target, DIY, Amazon, Stage fright, Insemination, Health, Research, Reproductive medicine, Female, Egg, Birth control, Science, Infertility, Frida

Until now, no one brand has offered a comprehensive set of conception support from preparation through insemination to (hopefully) celebration.

Key Points: 
  • Until now, no one brand has offered a comprehensive set of conception support from preparation through insemination to (hopefully) celebration.
  • CoQ10 is an antioxidant that maintains the health and number of eggs and Vitamin D supports a healthy ovarian reserve.
  • Frida Fertility’s one-stop shop for ovulation tracking helps women better understand their cycle so they know when it’s time to try.
  • The Frida Fertility line will be available at Target , CVS, Amazon and Frida.com beginning this month.

Fertility Treatments Global Market Report 2023: Growth in the Median Age of First Time Motherhood Bolsters Sector - ResearchAndMarkets.com

Retrieved on: 
Thursday, March 2, 2023
Health, Other Health, Benchmark, Woman, Infertility, Fertilisation, Fertility, Cooperman Barnabas Medical Center, Insurance, GDP, Create, Reproductive medicine, Agriculture, Twin, Egg, Mother, Family, IRMS, Growth, Genetics, Coronavirus, IVF, Acquisition, PH, Ageing, Birth control, Retail, Marketing, Video game, Science

The "Fertility Treatments Global Market Report 2023" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Fertility Treatments Global Market Report 2023" report has been added to ResearchAndMarkets.com's offering.
  • The growth in the median age of first-time motherhood combined with change in lifestyle increased the difficulty of conceiving, increasing the demand for fertility treatment.
  • The high cost and low success rate of In vitro fertilization (IVF) treatment is a major factor that limits the growth of the fertility treatments market.
  • Thus, the high cost and low success rate of IVF treatment restrict the growth of the fertility treatment market.

The Institute for Reproductive Medicine & Science (IRMS) welcomes Dr. Sarah M. Moustafa to their Livingston New Jersey practice

Retrieved on: 
Tuesday, July 26, 2022
Transfer, Psychology, Gynaecology, IUI, Freezing, View, Obstetrics and gynaecology, Harvard University, PGT, Highlands of Connecticut, New Jersey, New York, and Pennsylvania, Saint Barnabas Medical Center, Embryo, University of North Carolina at Chapel Hill, Johns Hopkins, Infertility, Reproduction, Magic, Reproductive system disease, Reproductive medicine, Family, Multimedia, Yale New Haven Hospital, Duke University, Patient, Cornell University, Department, IVF, NYU, IRMS, Love, Department of Obstetrics and Gynecology (Massachusetts General Hospital), Surrogacy, Child, Birth control, Obstetrics

LIVINGSTON, N.J., July 26, 2022 /PRNewswire/ -- IRMS is excited to announce that Dr. Sarah M. Moustafa has joined their practice.

Key Points: 
  • LIVINGSTON, N.J., July 26, 2022 /PRNewswire/ -- IRMS is excited to announce that Dr. Sarah M. Moustafa has joined their practice.
  • Dr. Moustafa is board certified in Obstetrics & Gynecology and board eligible in Reproductive Endocrinology & Infertility.
  • Dr. Moustafa earned her medical degree from Duke University, where she discovered her love of reproductive medicine and achieved highest honors in Obstetrics and Gynecology.
  • Sarah M. Moustafa)
    Dr. Moustafa is excited to see IRMS patients out of their Livingston, New Jersey office.

Worldwide Isotope Ratio Mass Spectrometry (IRMS) Industry to 2029 - Featuring Elementar, Isotopx, Nu Instruments, Sercon and Thermo Fisher Scientific - ResearchAndMarkets.com

Retrieved on: 
Thursday, June 30, 2022
Radiology, Health, COVID-19, IRMS, R. Graham Cooks, Lithium, Uranium

The "Global Isotope Ratio Mass Spectrometry (IRMS) Market, Forecast to 2029" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Global Isotope Ratio Mass Spectrometry (IRMS) Market, Forecast to 2029" report has been added to ResearchAndMarkets.com's offering.
  • This report focuses on the Isotope Ratio Mass Spectrometry (IRMS) market revenue at the global, regional, and company levels.
  • From a global perspective, this report represents overall Isotope Ratio Mass Spectrometry (IRMS) market size by analyzing historical data and future prospects.
  • Market Revenue of the Isotope Ratio Mass Spectrometry (IRMS) Market from 2017 to 2029.